During the last session, Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX)’s traded shares were 0.76 million, with the beta value of the company hitting 1.45. At the end of the trading day, the stock’s price was $0.29, reflecting an intraday loss of -20.19% or -$0.08. The 52-week high for the BDRX share is $8.81, that puts it down -2937.93 from that peak though still a striking -20.69% loss since the share price plummeted to a 52-week low of $0.35. The company’s market capitalization is $0.07M, and the average intraday trading volume over the past 10 days was 0.16 million shares, and the average trade volume was 1.45 million shares over the past three months.
Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX) trade information
Biodexa Pharmaceuticals Plc ADR (BDRX) registered a -20.19% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -20.19% in intraday trading to $0.29, hitting a weekly high. The stock’s 5-day price performance is -29.10%, and it has moved by -54.36% in 30 days. Based on these gigs, the overall price performance for the year is -94.63%. The short interest in Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX) is 85926.0 shares and it means that shorts have 0.5 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Biodexa Pharmaceuticals Plc ADR (BDRX) estimates and forecasts
Statistics show that Biodexa Pharmaceuticals Plc ADR has outperformed its competitors in share price, compared to the industry in which it operates. Biodexa Pharmaceuticals Plc ADR (BDRX) shares have gone down -72.43% during the last six months, with a year-to-date growth rate more than the industry average at 98.79% against 17.30.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 240k as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 370k by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 86.34%.
BDRX Dividends
Biodexa Pharmaceuticals Plc ADR is due to release its next quarterly earnings in October. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
